Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old
• People diagnosed with pancreatic cancer confirmed by a tissue or cell sample test
• People whose cancer cannot be removed by surgery, as assessed by a specialist team and imaging scans
• People whose cancer did not respond to a first round of treatment, including those whose cancer came back within 6 months of finishing early-stage (adjuvant or neoadjuvant) treatment
• People whose previous first-line treatment did not include platinum-based drugs or irinotecan
• People who have at least one measurable tumour that can be tracked during the trial
• People with a general health score of 0 to 2 on a standard activity scale (meaning able to carry out at least some daily activities) (confirm with trial site)
• People with an expected survival of at least 3 months
• People whose blood counts meet the required levels, including sufficient white blood cells, red blood cells, and platelets
• People whose liver function test results are within the acceptable range set by the trial
• People whose kidney function is within the acceptable range set by the trial
• People whose blood clotting test results are within the acceptable range set by the trial
• People with blocked bile ducts who have already had adequate drainage treatment
• People whose side effects from previous treatment have mostly recovered to a mild or baseline level before joining
• People who are not pregnant or breastfeeding; people who could become pregnant or father a child must use effective contraception during the trial and for 6 months after treatment ends
• People who understand the study process and have signed a written consent form

Who may not be able to join:

• People who have had another type of cancer in the past 5 years, except for certain fully treated skin cancers or non-invasive cancers
• People with fluid build-up around the lungs or abdomen that cannot be controlled
• People with known cancer that has spread to the brain or the lining of the brain or spine
• People who have taken certain strong medications that interact with liver enzymes (CYP3A4 or UGT1A1) within 3 weeks before the first dose (confirm with trial site)
• People who have had major surgery within 4 weeks before the first dose (minor procedures such as needle biopsies or certain drainage procedures may be acceptable — confirm with trial site)
• People with an active, uncontrolled infection (bacterial, viral, or fungal) that has not improved with appropriate treatment
• People with immune system deficiencies, including HIV, or active hepatitis B or C with virus levels above the thresholds set by the trial; people who are hepatitis B carriers with lower virus levels may be eligible if they are on antiviral treatment during the trial (confirm with trial site)
• People with serious ongoing health conditions such as poorly controlled diabetes, difficult-to-control high blood pressure, severe heart or brain vascular disease, kidney failure, liver failure, uncontrolled epilepsy, certain mental health conditions, or significant bowel problems such as bleeding, paralysis, or obstruction
• People experiencing significant diarrhoea (more than 4 extra bowel movements per day compared to normal) or severe stoma output that limits daily activities
• People with a blood protein (albumin) level at or below 3 g/dL
• People who have taken part in another clinical trial within 4 weeks before joining
• People assessed by the trial doctor as not suitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.